Get started
Author

Yuki Kanayama

Observed name: Kanayama, Yuki
ORCID: 0000-0002-8639-5212
Observed ORCID: 0000-0002-8639-5212
OpenAlex ID: A5015630164
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
2024 · Issei Saeki, Shigeo Shimose, et al. · PLoS ONE · 21
PDF
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
2024 · Atsushi Hiraoka, Toshifumi Tada, et al. · Hepatology Research · 20
PDF
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
2024 · Takeshi Hatanaka, Satoru Kakizaki, et al. · Alimentary Pharmacology & Therapeutics · 20
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
2025 · Shigeo Shimose, Issei Saeki, et al. · Hepatology International · 14
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
2025 · Takeshi Hatanaka, Yutaka Yata, et al. · Liver International · 11
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
2025 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Liver Cancer · 8
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
2025 · Ryu Sasaki, Shigeo Shimose, et al. · Liver International · 7
PDF
Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
2025 · Atsushi Naganuma, Satoru Kakizaki, et al. · Hepatology Research · 7
A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases
2023 · Ken Sato, Atsushi Naganuma, et al. · Biomedicines · 7
PDF
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Journal of Gastroenterology and Hepatology · 6
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
2026 · Hideko Ohama, Atsushi Hiraoka, et al. · Hepatology Research · 6
Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case
2015 · Hisao Imai, Nozomi Matsumura, et al. · Internal Medicine · 6
PDF
Comparison of Surgical Resection and Radiofrequency Ablation for Early‐Stage HCC Patients With Child–Pugh Class B
2025 · Takeshi Hatanaka, Satoru Kakizaki, et al. · Journal of Gastroenterology and Hepatology · 5
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient
2025 · Atsushi Hiraoka, Masatoshi Kudo, et al. · Oncology · 5
Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
2024 · Takanori Ito, Shigeo Shimose, et al. · Hepatology Research · 5
PDF
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Liver International · 4
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
2025 · Tetsu Tomonari, Shigeo Shimose, et al. · Hepatology Research · 4
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
2026 · Atsushi Hiraoka, Toshifumi Tada, et al. · Liver Cancer · 3
PDF
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
2025 · Takeshi Hatanaka, Yutaka Yata, et al. · Hepatology Research · 3
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma
2025 · Takeshi Hatanaka, Kei Shibuya, et al. · Hepatology Communications · 3
Association of Metabolic‐Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study
2025 · Takeshi Hatanaka, Shigeo Shimose, et al. · Hepatology Research · 3
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
2025 · Hideko Ohama, Atsushi Hiraoka, et al. · Journal of Gastroenterology · 3
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
2025 · Takanori Ito, Shigeo Shimose, et al. · Journal of Gastroenterology and Hepatology · 2
PDF
Tocilizumab for steroid-refractory hemophagocytic syndrome after durvalumab and tremelimumab for advanced hepatocellular carcinoma
2025 · Yuki Kanayama, Takeshi Hatanaka, et al. · Clinical Journal of Gastroenterology · 2
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab
2025 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Liver International · 2
Works count: 53
Citation count: 191
H-index: 7
I10-index: 5
Year
Topic
Type